ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K and RB pathways. Within the MAPK pathway ERK1/2 proteins exert a bottleneck function for transmitting mitogenic signals and activating cytoplasmic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer Ther
Hlavní autoři: Köhler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C., Tiv, Hong L., Knott, Aine R., Wilkens, Margaret K., Soroko, Kara M., Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A., Chambers, Emily S., Paweletz, Cloud P., Bhagwat, Shripad V., Manro, Jason R., Tiu, Ramon V., Jänne, Pasi A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026682/
https://ncbi.nlm.nih.gov/pubmed/33536188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0531
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky